Drug class
Second-generation, non-sedating selective peripheral H1-histamine receptor antagonist
Mechanism of action
Selectively antagonises peripheral histamine H1 receptors and has no meaningful affinity for muscarinic receptors at therapeutic concentrations.
General use cases
- Symptomatic treatment of seasonal and perennial allergic rhinoconjunctivitis
- Symptomatic treatment of urticaria; the cited UK 20 mg tablet authorisation is for adults and adolescents aged 12 years and over
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
